News & Information For Arrhythmia Clinicians


National tariff payment system 2017/18 and 2018/19

A set of prices and rules to help providers of NHS care and commissioners provide best value to their patients.

Read more

Patient - Doctor Discussion Guide

This guide is not for direct distribution to patients and is intended to support healthcare professional and patient discussion on atrial fibrillation (AF). 

It will take about ten minutes and will help you make the most of the consultation time.

Read more

Resuscitation To Recovery

Cardiopulmonary resuscitation (CPR) is attempted in nearly 30,000 people who suffer out-of-hospital cardiac arrest (OHCA) in England each year, but survival rates are low and compare unfavourably to a number of other countries.

Read more

National Audit of Cardiac Rhythm Management Devices - April 2015-March 2016













Frontline pharmacists: Making a difference for people with long term conditions

November 2016 - Royal Pharmaceutical Society

The Royal Pharmaceutical Society (RPS) believes that pharmacists have a crucial role to play in the support of people with long term conditions.

The management of long term conditions represents a significant strain on an already overstretched primary care system and an unnecessary burden on secondary care resources through avoidable hospital admissions.

The RPS believes that the expertise and clinical knowledge of pharmacists must be fully utilised to support people with long term conditions and help them to achieve the desired outcomes from their medicines, thereby making more efficient use of National Health Service (NHS) resources.

Read more

A qualitative study of decision-making about the implantation of cardioverter defibrillators and deactivation during end-of-life care

Holly Standing, Catherine Exley, Darren Flynn, Julian Hughes, Kerry Joyce, Trudie Lobban, Stephen Lord, Daniel Matlock, Janet M McComb, Paul Paes and Richard G Thomson

Read more


Anticoagulation Task Force White Paper:

Managing reversal of direct oral anticoagulants in emergency situations

Anticoagulation is the cornerstone of prevention and treatment of venous thromboembolism (VTE) and stroke prevention in patients with atrial fibrillation (AF). However, the mechanisms by which anticoagulants confer therapeutic benefit also increase the risk of bleeding. As such, reversal strategies are critical. Until recently, the direct oral anticoagulants (DOACs) dabigatran, rivaroxaban, apixaban, and edoxaban lacked a specific reversal agent. This report is based on findings from the Anticoagulation Education Task Force, which brought together patient groups and professionals representing different medical specialties with an interest in patient safety and expertise in AF, VTE, stroke, anticoagulation, and reversal agents, to discuss the current status of anticoagulation reversal and fundamental changes in management of bleeding associated with DOACs occasioned by the approval of idarucizumab, a specific reversal agent for dabigatran, as
well as recent clinical data on specific reversal agents for factor Xa inhibitors.

Read the report

View the presentation


British Cardiovascular Society Working Group Report:

Out-Of-Hours Cardiovascular Care: Management of Cardiac Emergencies and Hospital In-Patients

September 2016

Delivery of ‘out-of-hours’ cardiovascular care is of particular concern. Patients who require emergency treatment for heart disease should have immediate access to appropriate and timely investigation and treatment at any time of day or night. For many inpatients, however, the treatment pathway pauses overnight or at weekends as tests and senior medical staff may not be readily available. This variation in care can influence service quality and can delay discharge of patients from hospital with a knock-on effect for service delivery at other times during the week.

The British Cardiovascular Society commissioned a working group to gain some insight into the provision of ‘out-of-hours’ cardiovascular care across the United Kingdom. The working group report sets standards for the delivery of ‘out-of-hours’ cardiovascular services and makes recommendations to ensure equitable access to prompt, safe, effective and high quality care at all times.

Read more

Management of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia and Vasovagal Syncope

Satish Raj, Robert Sheldon - August 2016

Read more

Assessing fitness to drive - a guide for medical professionals

Click here to read the full article.

National Audit of Cardiac Rhythm Management Devices

Foreword from Trudie Lobban, CEO of the Arrhythmia Alliance  

Firstly, I would like to thank all the contributors to the audit from the designated cardiac implantation centres across the UK, and to the audit team and authors for producing the 10th UK Cardiac Rhythm Management Audit report. The robust data within the report must now be used as a catalyst and stimulus for action as it clearly demonstrates significant variation in implantation rates across the UK, and an overall unacceptable level of performance when compared to our European counterparts.  

Although this audit was not structured to measure patient outcomes related to the levels of implantation rates recorded, we can only assume that many patients and their families have suffered unnecessary negative outcomes through lack of cardiac implantation to manage their symptoms – and we must find ways to measure the direct impact of low implantation rates on patients, and how many patients this affects in the UK.   

Arrhythmia Alliance, the UK’s leading heart rhythm charity, believes in working together to improve the diagnosis, treatment and quality of life for all those affected by arrhythmias – and as stated in the recommendations of this report all patients with symptomatic bradycardia, without AV block, or with an arrhythmia and/or heart failure, where device implantation is the most appropriate treatment, MUST be able to have this treatment on the NHS. This is our mandate for action!   

The audit report raises a number of fundamental questions that need to be explored and addressed if we are to see any significant improvement in implantation rates at a local and national level, we believe this can only be done by driving through best practice that is resonant and applicable at the local level. Guidance on its own is not enough to ensure positive change.  

Where is the breakdown? Is it a lack of understanding and/or referral at primary care level, is there a need for better co‚Äźordination and provision of cardiac implantation services to manage local populations? Are there identifiable resource challenges? We can only hypothesise on the reasons until we get down to grass roots level to identify the problems and explore solutions.

During 2015 Arrhythmia Alliance ran a series of educational Cardiac Update meetings related to the management of arrhythmias and ran a number of pilot projects in areas where implantation rates needed to improve in partnership with local clinical physiologists, commissioners, primary care and industry.   In 2016 we intend to extend the pilot program to at least 10 areas in the UK where implantation rates need to improve and local, multidisciplinary teams want to work together to create local action plans to improve the overall management and treatment of patients with arrhythmias.

Trudie Lobban MBE FRCP (Edin)

Founder & CEO Arrhythmia Alliance

Read more


One year on - Why are patients still having unnecessary AF-related strokes?

In 2014 The National Institute for Health and Care Excellence (NICE) issued a clinical guideline on the management of atrial fibrillation (AF), which included recommendations on the use of optimal anticoagulation for prevention of AF-related stroke.

This report looks at data one year on to consider what has changed.

Read more


NOACs: Innovation in anticoagulation - optimising the prevention of AF-related stroke

This report sets out the current situation in the prevention of AF-related stroke and identifies how stakeholders across the NHS can embrace innovation in stroke prevention, utilising the availability of these new therapies to evaluate and optimise existing anticoagulation services, improving outcomes and easing the emotional and financial burden of this condition in England.

Read more

Get in touch for more help and information

+44 (0) 1789 867 501info@heartrhythmalliance.org


Send us your feedback

Download Resource

To download our information resource and receive regular updates from Arrhythmia Alliance please enter your details below*:

No thanks

*Please note you can unsubscribe from our mailing list at any time

This link will take you to the site

Stay on this site